Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101
Mafalda Costa Neves, Alex Giakoustidis, Gordon Stamp, Andy Gaya, Satvinder Mudan, Mafalda Costa Neves, Alex Giakoustidis, Gordon Stamp, Andy Gaya, Satvinder Mudan
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. Median survival for metastatic patients is six to nine months and survivors beyond one year are exceptional. Pancreatic cancer is resistant to conventional chemotherapy and is often diagnosed at advanced stages. However, immunotherapy is a rapidly advancing new treatment modality, which shows promise in many solid tumor types. We present a patient with metastatic pancreatic cancer who underwent a synchronous resection of the primary tumour (pancreatoduodenectomy) and metastatic site (left hepatectomy) after multimodality neoadjuvant treatment with gemcitabine, nab-paclitaxel, and immunotherapy backbone with IMM-101 (an intradermally applied immunomodulator), as well as consolidation chemoradiation. Pathology of the specimens showed a complete response in both sites of the disease. The patient remains alive four years from the initial diagnosis and continues on maintenance immunotherapy. This exceptional response to initial chemo-immunotherapy was followed by a novel and off-protocol approach of low-dose capecitabine and IMM-101 as a maintenance strategy. The survival benefit and sustained performance status could set this as a new paradigm for the treatment of oligometastatic pancreatic cancer following response to systemic therapy and immunotherapy..
Keywords: chemotherapy; imm-101; immunotherapy; neoadjuvant chemoradiation; pancreatic adenocarcinoma.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Figures
References
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. N Engl J Med. 2013;369:1691–1703.
- Gall TM, Tsakok M, Wasan H, Jiao LR. Postgrad Med J. Vol. 91. Oct: 2015. Pancreatic cancer: current management and treatment strategies; pp. 601–607.
- Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A, Juarez V. World J Gastroenterol. 2015;21:9297–9316.
- Mlecnik B, Bindea G, Pagès F, Galon J. Cancer Metastasis Rev. Vol. 30. Mar: 2011. Tumor immunosurveillance in human cancers; pp. 5–12.
- Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S. Ann Oncol. Vol. 23. May: 2012. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma; pp. 1314–1319.
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. N Engl J Med. 2011;364:1817–1825.
- Godbout JP, Glaser R. J Neuroimmune Pharmacol. Vol. 1. Dec: 2006. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer; pp. 421–427.
- Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. J Pathol. 2014;232:199–209.
- Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. Dalgleish AG, IMAGE 1 Trial Investigators. ASCO Meeting Abstracts. 2015;33:3051.
- The concept of hormesis in cancer therapy - Is less more? [Nov;2015 ];Gaya A, Akle CA, Mudan S, Grange J. Cureus. 2015 7:0.
Source: PubMed